Epstein-Barr virus infection and mitogen stimulation of normal B cells induces wild-type p53 without subsequent growth arrest or apoptosis

Journal of General Virology

Volumn 80, Issue 4, 1999, Pages 987-995

  Pokrovskaja, Katja ^a   Okan, Ismail ^a   Kashuba, Elena ^a   Löwbeer, Maria ^a   Klein, George ^a   Szekely, Laszlo ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 39; INTERLEUKIN 4; MITOGENIC AGENT; PROTEIN P53;

ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; DNA CONTENT; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMAGE ANALYSIS; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0032957430     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-80-4-987     Document Type: Article

References (45)

1. Allday, M. J., Inman, G. J., Crawford, D. H. & Farrell, P. J. (1995a). DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO Journal 14, 4994-5005.
2. Allday, M. J., Sinclair, A., Parker, G., Crawford, D. H. & Farrell, P. J. (1995b). Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO Journal 14, 1382-1391.
3. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. & Vogelstein, B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915.
4. Banchereau, J., de Paoli, P., Valle, A., Garcia, E. & Rousset, F. (1991). Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251, 70-72.
5. Blaydes, J. P., Gire, V., Rowson, J. M. & Wynford-Thomas, D. (1997). Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene 14, 1859-1868.
6. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T. & Hannon, G. J. (1995). Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377, 552-557.
7. Caelles, C., Helmberg, A. & Karin, M. (1994). p53-dependent apoptosis in the absence of transcriptional activation of p53 target genes (see comments). Nature 370, 220-223.
8. Chen, W. & Cooper, N. R. (1996). Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity. Journal of Virology 70, 4849-4853.
9. Chen, J., Wu, X., Lin, J. & Levine, A. J. (1996a). mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Molecular and Cellular Biology 16, 2445-2452.
10. Chen, X., Ko, L. J., Jayaraman, L. & Prives, C. (1996b). p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes and Development 10, 2438-2451.
11. Crook, T., Marston, N. J., Sara, E. A. & Vousden, K. H. (1994). Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79, 817-827.
12. Deng, C., Zhang, P., Harper, J. W., Elledge, S. J. & Leder, P. (1995). Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684.
13. Edwards, R. H. & Raab-Traub, N. (1994). Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas. Journal of Virology 68, 1309-1315.
14. Farrell, P. J., Allan, G. J., Shanahan, F., Vousden, K. H. & Crook, T. (1991). p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO Journal 10, 2879-2887.
15. Finke, J., Rowe, M., Ernberg, I., Rosen, A., Dillner, J. & Klein, G. (1987). Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. Journal of Virology 61, 3870-3878.
16. Fries, K. L., Miller, W. E. & Raab-Traub, N. (1996). Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. Journal of Virology 70, 8653-8659.
17. Garrone, P., Neidhardt, E. M., Garcia, E., Galibert, L., van Kooten, C. & Banchereau, J. (1995). Fas ligation induces apoptosis of CD40-activated human B lymphocytes. Journal of Experimental Medicine 182, 1265-1273.
18. Gavrieli, Y., Sherman, Y. & Ben-Sasson, S. A. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. Journal of Cell Biology 119, 493-501.
19. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
20. Jones, S. N., Roe, A. E., Donehower, L. A. & Bradley, A. (1995). Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208.
21. Kieff, E. (1996). Epstein-Barr virus and its replication. In Fields Virology, 3rd edn, pp. 2343-2396. Edited by B. N. Fields, D. M. Knipe & P. M. Howley. Philadelphia: Lippincott-Raven.
22. Ko, L. J. & Prives, C. (1996). p53: puzzle and paradigm. Genes and Development 10, 1054-1072.
23. Kubbutat, M. H., Jones, S. N. & Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
24. Lalle, P., Moyret-Lalle, C., Wang, Q., Vialle, J.-M., Navarro, C., Bressac-de Paillerets, B., Magaud, J.-P. & Ozturk, M. (1995). Genomic stability and wild type p53 function of lymphoblastoid cells with germ-line p53 mutation. Oncogene 10, 2447-2454.
25. Lassus, P., Ferlin, M., Piette, J. & Hibner, U. (1996). Anti-apoptotic activity of low levels of wild-type p53. EMBO Journal 15, 4566-4573.
26. Liu, Y. J., Joshua, D. E., Williams, G. T., Smith, C. A., Gordon, J. & MacLennan, I. C. (1989). Mechanism of antigen-driven selection in germinal centres. Nature 342, 929-931.
27. Lukas, J., Bartkova, J., Welcker, M., Petersen, O. W., Peters, G., Strauss, M. & Bartek, J. (1995). Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 10, 2125-2134.
28. Lutzker, S. G. & Levine, A. J. (1996). A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Medicine 2, 804-810.
29. Maestro, R., Gloghini, A., Doglioni, C., Piccinin, S., Vukosavljevic, T., Gasparotto, D., Carbone, A. & Boiocchi, M. (1997). Human non-Hodgkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21. Blood 89, 2523-2528.
30. Mercer, W. E. & Baserga, R. (1985). Expression of the p53 protein during the cell cycle of human peripheral blood lymphocytes. Experimental Cell Research 160, 31-46.
31. Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. (1995). Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206.
32. Okan, I., Wang, Y., Chen, F., Hu, L. F., Imreh, S., Klein, G. & Wiman, K. G. (1995). The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 11, 1027-1031.
33. Oren, M., Reich, N. C. & Levine, A. J. (1982). Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Molecular and Cellular Biology 2, 443-449.
34. Pagano, M., Theodoras, A. M., Tam, S. W. & Draetta, G. F. (1994). Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes and Development 8, 1627-1639.
35. Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D. & Levine, A. J. (1993). The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proceedings of the National Academy of Sciences, USA 90, 11623-11627.
36. Picksley, S. M. & Lane, D. P. (1993). The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15, 689-690.
37. Pietenpol, J. A., Tokino, T., Thiagalingam, S., el Deiry, W. S., Kinzler, K. W. & Vogelstein, B. (1994). Sequence-specific transcriptional activation is essential for growth suppression by p53. Proceedings of the National Academy of Sciences, USA 91, 1998-2002.
38. Polyak, K., Waldman, T., He, T. C., Kinzler, K. W. & Vogelstein, B. (1996). Genetic determinants of p53-induced apoptosis and growth arrest. Genes and Development 10, 1945-1952.
39. Reich, N. C. & Levine, A. J. (1984). Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 308, 199-201.
40. Selivanova, G. & Wiman, K. G. (1995). p53: a cell cycle regulator activated by DNA damage. Advances in Cancer Research 66, 143-180.
41. Shohat, O., Greenberg, M., Reisman, D., Oren, M. & Rotter, V. (1987). Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene 1, 277-283.
42. Szekely, L., Pokrovskaja, K., Jiang, W.-Q., Selivanova, G., Löwbeer, M., Ringertz, N., Klein, G. & Wiman, K. G. (1995). Resting B-cells, EBV-infected B-blasts and established lymphoblastoid cell lines differ in their RB, p53 and EBNA-5 expression patterns. Oncogene 10, 1869-1874.
43. Wendel-Hansen, V., Rosen, A. & Klein, G. (1987). EBV-transformed lymphoblastoid cell lines down-regulate EBNA in parallel with secretory differentiation. International Journal of Cancer 39, 404-408.
44. Williams, K. J., Heighway, J., Birch, J. M., Norton, J. D. & Scott, D. (1996). No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines. British Journal of Cancer 74, 698-703.
45. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. & Oren, M. (1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347.